This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Simple Secrets Anyone Can Use to Reach Early Retirement - September 25, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.76, marking a +1.71% move from the previous day.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 22, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - September 22, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Roche's Tecentriq + Avastin Gets Positive CHMP Opinion for HCC
by Zacks Equity Research
Roche's (RHHBY) combination of immuno-oncology drug, Tecentriq, and Avastin gets positive CHMP opinion for the treatment of advanced or unresectable HCC.
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
by Zacks Equity Research
Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.
Bristol Myers Squibb (BMY) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.45, marking a -0.13% move from the previous day.
The Zacks Analyst Blog Highlights: Facebook, McDonald's, Bristol-Myers Squibb, Netflix, and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, McDonald's, Bristol-Myers Squibb, Netflix, and U.S. Bancorp
The Extreme Risks of Trading Your Own Retirement Assets - September 14, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Top Research Reports for Facebook, McDonalds & Bristol-Myers
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), McDonalds (MCD) and Bristol-Myers Squibb (BMY).
Bristol Myers Squibb (BMY) Stock Moves -1.34%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $58.29 in the latest trading session, marking a -1.34% move from the prior day.
3 Top Dividend Stocks to Maximize Your Retirement Income - September 10, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Easy Investing Secrets to an Early Retirement - September 09, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
AVEO's NDA for Fotivda on Track, FDA Verdict Due Next Year
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.
Why Is Bristol Myers (BMY) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol Myers Squibb (BMY) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.95, moving -0.17% from the previous trading session.
3 Top Dividend Stocks to Maximize Your Retirement Income - September 04, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
How Trading Your Own Retirement Can Fleece Your Financial Future - September 04, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
by Zacks Equity Research
Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
Powerful Proof Anyone Can Invest for an Early Retirement - August 31, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.